Yield Growth aims to disrupt the $4.2 trillion-dollar global wellness market, primarily providing luxury hemp and cannabis-infused products.
In November 2019, The Yield Growth Corp acquired a portfolio of 126 psilocybin formulas via its subsidiary, Flourish Mushroom Labs. Their catalogue of formulas now stands at around 145, which it seeks to apply to the booming functional food market.
Yield Growth’s subsidiary, Flourish Mushroom Labs, has made its ambitions to produce psilocybin very clear; most notably through the formation of a Company in Saint Vincent and the Grenadines. Acres Flourish Labs plans to construct a purpose-built laboratory for the cultivation of psilocybin mushrooms, and for R&D activities.
Flourish Mushroom Labs also acquired a founding interest in Translational Life Sciences Inc., a biotechnology company seeking to develop formulas containing restricted substances (such as cannabis and psilocybin) that may have medical applications.
Flourish has already begun to file provisional US patents for their psilocybin ‘treatments’, including the administering of psilocybin/psilocin microdoses in order to encourage weight loss via the increase of metabolism and limiting of food cravings.
News & Interviews
Note: due to the emergent nature of the psychedelics sector, many publicly listed companies do not have complete valuation or financial data.